Canada Markets closed

Graphite Bio, Inc. (GRPH)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.0600+0.0900 (+2.27%)
At close: 04:00PM EDT
4.2600 +0.20 (+4.93%)
After hours: 06:00PM EDT
Full screen
Loading interactive chart...
  • Business Wire

    Graphite Bio Reports Recent Business Progress and Second Quarter 2022 Financial Results

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today reported recent business progress and second quarter 2022 financial results.

  • Business Wire

    Graphite Bio Doses First Patient with Investigational Gene Editing Therapy GPH101 for Sickle Cell Disease

    SOUTH SAN FRANCISCO, Calif., August 11, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to cure serious diseases, today announced that the first patient has been dosed with GPH101, now called nulabeglogene autogedtemcel (nula-cel), in the company’s Phase 1/2 CEDAR trial in people with sickle cell disease (SCD). Nula-cel is an investigational gene e

  • Business Wire

    Graphite Bio Announces Participation in Jefferies Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., June 01, 2022--Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company harnessing the power of high-efficiency precision gene repair to develop therapies with the potential to treat or cure serious diseases, today announced that members of the management team will present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4 p.m. ET.